Subgrouping in Chronic Fatigue Syndrome Based on Actigraphy and Illness Severity

Zaturenskaya, Mariya; Jason, Leonard A.; Torres-Harding, Susan; Tryon, Warren W.

doi:10.2174/1874196700902010020

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some authors attempted to subtype ME/CFS patients based on differences in gene expression profiles in order to approach particular etiological factors [162,167,168]. A symptom-based approximation of the disease has had success in identifying musculoskeletal, inflammatory, and neurological subtypes [169]. One of those studies enrolled patients with a defined ME/CFS phenotype and compared them to healthy blood donors using a microarray that represents the entire human genome and with quantitative PCR (qPCR) confirmation.…”

Section: Genetic Predispositionmentioning

confidence: 99%

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review

et al. 2019

View full text Add to dashboard Cite

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown aetiology that is recognized by the World Health Organization (WHO) and the United States Center for Disease Control and Prevention (US CDC) as a disorder of the brain. The disease predominantly affects adults, with a peak age of onset of between 20 and 45 years with a female to male ratio of 3:1. Although the clinical features of the disease have been well established within diagnostic criteria, the diagnosis of ME/CFS is still of exclusion, meaning that other medical conditions must be ruled out. The pathophysiological mechanisms are unclear but the neuro-immuno-endocrinological pattern of CFS patients gleaned from various studies indicates that these three pillars may be the key point to understand the complexity of the disease. At the moment, there are no specific pharmacological therapies to treat the disease, but several studies’ aims and therapeutic approaches have been described in order to benefit patients’ prognosis, symptomatology relief, and the recovery of pre-existing function. This review presents a pathophysiological approach to understanding the essential concepts of ME/CFS, with an emphasis on the population, clinical, and genetic concepts associated with ME/CFS.

show abstract

Section: Genetic Predispositionmentioning

confidence: 99%

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a severe physically and cognitively incapacitating illness diagnosed by symptom-specific criteria [1][2][3]. CFS/ME presents as a multifactorial illness that varies greatly in the nature of onset and severity of symptom presentation [1,2,4,5]. A key characteristic is debilitating fatigue that lasts for a period of 6 or more months that has a critical effect on a patient's daily activities are critically affected [1][2][3]6].The severity of symptoms can vary greatly in CFS/ME.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)

Hardcastle

Brenu²,

Johnston³

et al. 2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Objective: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a disabling illness, characterised by persistent, debilitating fatigue and a multitude of symptoms. Immunological alterations are prominent in CFS/ME cases, however little is known about the relationship between CFS/ME severity and the extent of immunological dysfunction. The purpose of this study was to assess innate and adaptive immune cell phenotypes and function of two groups of CFS/ME patients, bedridden (severe) and mobile (moderate). Methods: CFS/ME participants were defined using the Centres for Disease Prevention and Control (1994 CDC) Criteria for CFS/ME. Participants were grouped into healthy controls (n=22, age=40.14 ± 2.38), moderate/ mobile (n=23; age=42.52 ± 2.63) and severe/bedridden (n=18; age=39.56 ± 1.51) CFS/ME patients. Flow cytometric protocols were used to examine neutrophil, monocyte, dendritic cells (DCs), iNKT, Treg, B, γδ and CD8 + T cell phenotypes, NK cytotoxic activity and receptors. Results: The present data found that CFS/ME patients demonstrated significant decreases in NK cytotoxic activity, transitional and regulatory B cells, γδ1T cells, KIR2DL1/DS1, CD94 + and KIR2DL2/L3. Significant increases in CD56-CD16 + NKs, CD56 dim CD16-and CD56 bright CD16-/dim NKs, DCs, iNKT phenotypes, memory and naive B cells were also shown in CFS/ME participants. Severe CFS/ME patients demonstrated increased CD14-CD16 + DCs, memory and naïve B cells, total iNKT, iNKT cell and NK phenotypes compared to moderate CFS/ME patients. Conclusion: This study is the first to determine alterations in NK, iNKT, B, DC and γδ T cell phenotypes in both moderate and severe CFS/ME patients. Immunological alterations are present in innate and adaptive immune cells and sometimes, immune deregulation appears worse in CFS/ME patients with more severe symptoms. It may be appropriate for CFS/ME patient severity subgroups to be distinguished in both clinical and research settings to extricate further immunological pathologies that may not have been previously reported.

show abstract

Severity Scales for Use in Primary Health Care to Assess Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Hardcastle

Brenu

Johnston

et al. 2014

Health Care for Women International

View full text Add to dashboard Cite

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a physical and cognitive disabling illness, characterized by severe fatigue and a range of physiological symptoms, that primarily affects women. The immense variation in clinical presentation suggests differences in severity based on symptomology and physical and cognitive functional capacities. In this article, we examine a number of severity scales used in assessing severity of patients with CFS/ME and the clinical aspects of CFS/ME severity subgroups. The use of severity scales may be important in CFS/ME because it permits the establishment of subgroups that may improve accuracy in both clinical and research settings.

show abstract

Subgrouping in Chronic Fatigue Syndrome Based on Actigraphy and Illness Severity

Cited by 4 publications

References 32 publications

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review

Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)

Severity Scales for Use in Primary Health Care to Assess Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Contact Info

Product

Resources

About